IP Library Granted Patent US 9,644,186
Granted Patent B2
US 9,644,186 · App. 15/063,046 · Granted May 9, 2017

Simplified basic media for human pluripotent cell culture

Inventors: Guokai Chen (Rockville, MD); James A. Thomson (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation
C12N5/0696C12N5/0606C12N2500/02C12N2500/32C12N2500/38C12N2500/90C12N2500/98C12N2501/105C12N2501/115C12N2501/119C12N2501/15C12N2501/33C12N2501/727C12N2501/845C12N2501/998
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,644,186
App. No.
15/063,046
Granted
May 9, 2017
Kind
B2
Abstract

Fully defined media that support pluripotent cell viability, proliferation, cloning, and derivation, as well as methods and compositions including these media are described. Methods for deriving iPS cells from adult individuals under defined, xeno-free conditions are also described.

Claims (13)

1. A method for deriving an induced pluripotent stem (iPS) cell under defined conditions, the method comprising the step of:

introducing reprogramming factors into a somatic cell in a defined, albumin-free medium that is free of any component obtained from a non-human animal, the medium comprising water, salts, amino acids, vitamins, glucose, an FGF, selenium, transferrin, one of insulin, IGF1, and IGF2, and one of TGF-β and NODAL, each in an amount sufficient to support reprogramming of the somatic cell to derive an iPS cell.

2. The method of claim 1 , wherein the IGF1 is Long-IGF1.

3. The method of claim 1 , wherein the reprogramming step comprises contacting the cell with TGFβ for 5-10 days.

4. The method of claim 1 , further comprising the steps of:

removing the TGFβ after 5-10 days; and

contacting the cells with a medium consisting essentially of:

water, salts, amino acids, vitamins, glucose, an FGF, selenium, one of insulin, IGF1, and IGF2, and transferrin.

5. The method of claim 1 , wherein the reprogramming step comprises contacting the cell with hydrocortisone.

6. The method of claim 1 , wherein the reprogramming step comprises contacting the cell with butyrate.

7. The method of claim 1 , wherein the somatic cell is an adult somatic cell.

8. The method of claim 1 , wherein the reprogramming step comprises introducing a viral vector into the somatic cell.

9. The method of claim 1 , wherein the reprogramming step comprises introducing an episomal vector into the somatic cell.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 16, 2018
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046172/0846 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2016
From: THOMSON, JAMES; CHEN, GUOKAI
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 040734/0122 →
Continuity (4)
Division 13341059 · Dec 30, 2011
Continuation In Part 13204354 · Aug 5, 2011
Provisional Application 61371128 · Aug 5, 2010
Related Publication 20160194611A1 · Jul 7, 2016